Vaccine News and Research

Latest Vaccine News and Research

DOR Biopharma to raise $3.85 million from institutional investors

DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

25 Sep 2009

AABM Team wins two medals in a national contest

The Aquatic Animal Bio-Medicine R&D Team (AABM Team) of National Cheng Kung University (NCKU) in Taiwan, led by Distinguished Prof. Huey-Lang Yang from Institute of Biotechnology, won two medals out of more than 100 teams in the national contest, “2009 Crazy Idea – King of Practical Applications on Creative Researches and Development of Biotechnology,” organized by the Industrial Development Bureau of the Ministry of Economic Affairs, Taiwan.

25 Sep 2009

Registered Nurses of CNA/NNOC requests meeting with HCA regarding its policy on use of surgical masks

In response to a new policy imposed by the Hospital Corporation of America (HCA) mandating flu shots for all employees and requiring masks, the Registered Nurses of the California Nurses Association/National Nurses Organizing Committee (CNA/NNOC) have requested a meeting with hospital executives on behalf of the chain's 50,000 RNs over this life-and-death issue.

25 Sep 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

Members of HealthSpring to receive costs of administering the H1N1 flu vaccination

HealthSpring will cover the costs of administering the H1N1 (swine) flu vaccination to its members as the vaccine becomes available.

25 Sep 2009

Collaboration for the evaluation of peptide copolymer technology

Peptimmune, Inc., a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

25 Sep 2009

Phase III clinical trial of investigational HIV vaccine regimen complete

Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.

25 Sep 2009

Seasonal and H1N1 flu vaccines from Priority Health

Priority Health has announced its coverage of both the seasonal flu and H1N1 flu vaccines. “Preventing the flu through immunization is the best way to keep yourself and your family healthy,” said John Fox, M.D., associate vice president of Medical Affairs at Priority Health. “We encourage our members to receive both vaccines to protect themselves against the two viruses.”

25 Sep 2009

Three antibodies dried using EnWave's freezeREV vial dehydration technology

EnWave Corporation ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology.

25 Sep 2009

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Investigational vaccine shows modest potential for protecting against HIV infection

For the first time, scientists say an investigational vaccine has modest potential for protecting people against HIV infection, the Associated Press reports. "The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by ... 31 percent in the world's largest [HIV] vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok," the news service writes (Marchione/Casey, 9/24).

25 Sep 2009

Experimental HIV vaccine shows promise

An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."

25 Sep 2009

Only 40% of parents will get their child vaccinated against H1N1?

The latest C.S. Mott Children's Hospital National Poll on Children's Health finds only 40 percent of parents indicate they will get their children vaccinated against H1N1 flu -- while 54 percent of parents indicate they will get their children vaccinated against seasonal flu. Among parents who do not plan to get their children vaccinated against H1N1 flu, 46 percent indicate they are not worried about their children getting H1N1 flu, while 20 percent believe H1N1 flu is not serious.

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Liquidia founder Dr. Joseph DeSimone honoured with the NIH Director’s Pioneer Award

Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director’s Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.

24 Sep 2009

Commitments announced at the Clinton Global Initiative

The second day of the Fifth Annual Meeting of the Clinton Global Initiative (CGI) came to a close with a special session on Northern Ireland, following afternoon plenary and breakout sessions that focused on harnessing innovation for development.

24 Sep 2009

First Edition: September 24, 2009

Today's headlines shed light on developments during the second day of the Finance Committee's health bill mark up.

24 Sep 2009

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

HPV screening and vaccination programmes could eradicate cervical cancer

Cervical cancer could be eradicated within the next 50 years if countries implement national screening programmes based on detection of the human papilloma virus (HPV), which causes the disease, together with vaccination programmes against the virus, according to a cervical cancer screening expert.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009